Study Explores Colchicine's Role in Preventing PAD
Complications
MELBOURNE — Monash University and Eastern Health have initiated a clinical trial to examine the efficacy of Colchicine, a drug commonly used for gout, in reducing the risk of peripheral artery disease (PAD). The trial, part of the international LEADER-PAD study, involves over 6000 participants globally, with 1000 expected from Australia.
Peripheral artery disease, which affects one in five individuals over 75, is characterised by the narrowing of arteries supplying blood to the legs, often due to atherosclerosis. Associate Professor Anthony Dear from Monash University is leading the Melbourne phase of the trial, highlighting the potential impact of Colchicine on patient outcomes.
The Hidden Risks of Peripheral Artery Disease
Associate Professor Dear emphasised the drug’s potential benefits, saying, “Colchicine is inexpensive, safe, and suitable for long-term use. It could significantly benefit patients worldwide by preventing severe complications such as leg ulcers and amputations.” Despite the severity of PAD, it remains under-researched and often undiagnosed, leading to poor outcomes for many patients.
The trial, originating in Canada, operates as a randomized, placebo-controlled study to evaluate Colchicine’s effectiveness in improving cardiovascular health in PAD patients. According to Dear, the condition’s subtle onset often results in neglect, earning it the nickname “the Cinderella of cardiovascular disease.”
In addition to reducing the risk of severe complications, the study aims to provide comprehensive data on the long-term effects of Colchicine use in diverse populations. Researchers hope that the findings will pave the way for enhanced treatment protocols and increased awareness of PAD, improving patient care. The trial’s outcomes could potentially shift current medical practices and offer a new pathway for managing cardiovascular diseases associated with PAD.
Source: newshub.medianet.com.au
Last updated: 4 April 2026, 8:23 pm
